Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 4, 1997

View Archived Issues

Chiron: Q3 1997 highlights

Sequus: Q3 1997 highlights

SangStat Medical: Q3 1997 highlights

Celgene: Q3 1997 highlights

Bausch & Lomb to acquire Chiron Vision

Promising phase III results reported for KeraVision ring

Factor Xa inhibitors prepared at DuPont Merck

NeuroSearch describes tropane derivatives that inhibit neurotransmitter reuptake

Novel class of compound enhances IFN-gamma and NT-3 activity

HMR claims dual H1/NK1 antagonists for allergic/inflammatory disorders

Bristol-Myers Squibb prepares protein farnesyltransferase inhibitors

New alpha-1-antitrypsin test launched in U.S.

Chiroscience develops new TNF/PDE IV inhibitors

Clinical trials planned for CEP-1347/KT-7515 in AD

Sequana and Glaxo Wellcome revise diabetes/obesity alliance

Oral prodrugs of novel carbapenems prepared at Wyeth-Ayerst

Preclinical results with Ergo Science's neuroendocrine resetting therapy

Phase III safety and efficacy data reported for one-alpha D2

GelTex submits NDA for RenaGel

Arris and Sequana to merge

New human rabies vaccine cleared in U.S.

Novel antihypertensive agent developed in Taiwan

Effects of riluzole on ischemia-induced glutamate accumulation in rabbits

U.S. patent issued for ABS 200 series

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 17, 2026.
Biohaven reports details on discovery of BHV-2100
BioWorld Science
Transient receptor potential melastatin 3 (TRPM3) is a calcium-permeable TRP channel that is highly expressed in somatosensory neurons, including nociceptors of...
New GABA(B) receptor PAMs revealed in Addex Pharma patents
BioWorld Science
Addex Pharma SA has disclosed new GABA(B) receptor positive allosteric modulators (PAMs) potentially useful for the treatment of chronic cough, urinary...
Meta-analysis: Anti-amyloid Alzheimer’s drugs not ‘clinically meaningful’
BioWorld
The ongoing controversy over the effectiveness of anti-amyloid drugs is about to get more heated, after a review of clinical trials showed statistically...
Novel caspase-2 inhibitor shows in vivo neuroprotective effects
BioWorld Science
Caspase-2-mediated cleavage of tau at Asp314 generates a neurotoxic fragment, Δtau314, that drives early synaptic dysfunction in Alzheimer’s disease (AD) and...